NASDAQ
03.06.24
21:59 Uhr
0,149 US-Dollar
+0,004
+2,76 %
+2,76 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.02. | Galera Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.12.24 | Galera Therapeutics completes acquisition of Nova Pharmaceuticals | 381 | GlobeNewswire (Europe) | Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase... ► Artikel lesen | |
| 31.12.24 | Galera Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| GALERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.12.24 | Galera Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.12.24 | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.11.24 | Galera Therapeutics, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 18.10.24 | Galera Therapeutics, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 06.09.24 | NSE - Galera Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 4 | SEC Filings | ||
| 04.09.24 | Delisting of Securities of Liberty Resources Acquisition Corp.; Achari Ventures Holdings Corp. I; PetVivo Holdings, Inc.; Galera Therapeutics, Inc.; Clean Energy Special Situations Corp.; Capitalworks Emerging Markets Acquisition ... | 127 | GlobeNewswire (Europe) | NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, units, and warrants of Liberty Resources Acquisition Corp. Liberty Resources... ► Artikel lesen | |
| 14.08.24 | Galera Therapeutics: Galera Announces Board Approval of Complete Liquidation and Dissolution | 183 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary... ► Artikel lesen | |
| 13.05.24 | Galera Therapeutics: Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates | 248 | GlobeNewswire (Europe) | MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics... ► Artikel lesen | |
| 03.05.24 | Galera Therapeutics: Galera Adopts Limited Duration Stockholder Rights Agreement | 307 | GlobeNewswire (Europe) | MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the... ► Artikel lesen | |
| 28.03.24 | Galera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates | 312 | GlobeNewswire (Europe) | MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,150 | -0,43 % | Evotec Aktie: Wechselwirkungen im internationalen Kontext | Die Evotec-Aktie verzeichnete am Handelstag einen bemerkenswerten Aufschwung und kletterte im XETRA-Handel um 5,3 Prozent auf 8,97 Euro. Das Handelsvolumen erreichte dabei 475.841 Aktien, wobei das... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,400 | -5,16 % | Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why | ||
| MAINZ BIOMED | 5,695 | -100,00 % | EQS-News: Mainz BioMed N.V.: Darmkrebsmonat März: Mainz Biomed setzt sich für einen Wechsel von Diagnose zur Prävention ein | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Darmkrebsmonat März: Mainz Biomed setzt sich für einen Wechsel von Diagnose zur Prävention ein
03.03.2025... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 17.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 17.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 17.02.2025ISIN NameCA00208E3077 ATI... ► Artikel lesen | |
| GALAPAGOS NV | 24,800 | +0,08 % | Galapagos NV: Galapagos to Present at Upcoming Investor Conferences | Mechelen, Belgium; February 24, 2025, 22:01 CET - Galapagos NVBarclays 27th Annual Global Healthcare ConferenceDate: Wednesday, March 12, 2025Location: Miami, FLCorporate Presentation: 11:00 - 11:25... ► Artikel lesen | |
| CENTOGENE | 0,150 | +25,00 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,270 | +1,50 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| NOVOCURE | 18,150 | +3,39 % | Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update | Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung cancer, commercial... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,445 | +7,23 % | Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones | - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| AC IMMUNE | 2,305 | +0,66 % | AC Immune SA: AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious... ► Artikel lesen | |
| CHIMERIX | 4,815 | +0,31 % | CHIMERIX INC - 8-K, Current Report | ||
| CYTOMX THERAPEUTICS | 0,630 | +0,88 % | CytomX Therapeutics Aktie: Noch ein Nackenschlag? | Die CytomX Therapeutics Aktie verzeichnete am 01. März 2025 einen leichten Kursgewinn von 2,19% und notierte bei 0,69 USD. Diese positive Tagesentwicklung steht allerdings im Kontrast zu den erheblichen... ► Artikel lesen | |
| CYTOKINETICS | 41,600 | +1,46 % | Smart Money Is Betting Big In CYTK Options | ||
| SPERO THERAPEUTICS | 0,731 | -0,95 % | Spero Therapeutics, Inc. - 8-K, Current Report | ||
| EIGER BIOPHARMACEUTICALS | 5,840 | -100,00 % | Eiger Biopharmaceuticals concludes chapter 11 process |
GALERA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,149 Euro und damit +2,76 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALERA THERAPEUTICS INC finden Sie auf Wallstreet Online.
